LGND NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Ligand Pharmaceuticals Incorporated · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 287.5 USD
-4.3% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 24.2% above the Trend Line and sits at 79.9% of its 52-week range. The latest completed week returned -4.3%, after a -10.0% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. Options positioning is bearish with 43/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: earnings are due in 3d.

Setup score 69 out of 100
Latest Close 287.5 USD 31 Jul 2026
1W Return -4.3% latest completed week
4W Return -10.0% short-term follow-through
12W Return 29.9% quarterly tape
Trend Breadth 100.0% 52 of 52 weeks active
Volume Ratio 1.0x vs 13-week average
What is working
  • The trend backdrop is active with a 55-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 8 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.3% Latest completed week; four-week move -10.0%. Indicator stack 100/68 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 57.66% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bearish 43/100 conviction; expected move 9.2%. News sentiment 55/100 61 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 24.2% above the Trend Line and sits at 79.9% of its 52-week range. The latest completed week returned -4.3%, after a -10.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9712-week average 0.84

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.97Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers88 reversal markers

No recent accumulation markers. 8 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -10.0% over four weeks, 29.9% over 12 weeks, and 116.7% over one year. The current trend has remained active for 55 consecutive weeks.

Performance by holding period

1W-4.3%
4W-10.0%
12W29.9%
26W49.7%
52W116.7%
Active trend streak55 weeks
Active weeks in one year52
Trend breadth100.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.14Latest activity-pressure read.
Pressure change-32.7%Four-week change in activity pressure.
Leadership26.60Latest relative-leadership reading.
RS change-37.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 89%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength47/100Blend of value, momentum, and quality. Underlying universe rank 54; rank 1 is best.
Value4/100Relative valuation strength. Underlying universe rank 97; rank 1 is best.
Quality86/100Profitability and accounting quality. Underlying universe rank 15; rank 1 is best.
Momentum97/100Medium-term price momentum. Underlying universe rank 4; rank 1 is best.
Growth86/100Revenue and earnings growth. Underlying universe rank 15; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework25/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
37.5x
Price divided by trailing earnings.
Price / sales
21.0x
Market value relative to trailing revenue.
EV / EBITDA
27.4x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
2.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
98.6%
Gross profit retained from each unit of revenue.
Operating margin
68.4%
Operating profit retained from revenue.
Free-cash-flow margin
45.1%
Free cash flow generated from revenue.
Return on invested capital
11.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
51.2%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
76.7%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.3%
Net share repurchases relative to market value.
Shareholder yield
0.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBearish

LGND shows bearish options pressure with a 43/100 conviction score, put-call volume ratio of 2.50, expected move of 9.2%, and Sharemaestro trend signal active.

Conviction43/100
Expected move9.2%
Put/call volume2.50
Pressure-38
Speculation18
Volatility71
Trend agreement59
Open options detail
Insider activity7 / 13

7 acquisitions and 13 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment55/100

Weighted news tone is neutral across 61 relevant articles.

18 positive · 40 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move9.2%Nearest-chain priced movement where available.
52-week drawdown-12.0%Distance below the 52-week high.
13-week volatility5.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+13.1%Week of 17 Apr.
Worst week-4.6%Week of 27 Mar.
Latest week-4.3%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains8
Flat weeks0
Modest losses8
Sharp losses3
Recent vol5.0%13-week weekly-return volatility.
Base vol4.7%52-week weekly-return volatility.
Up/down split32/20Count of positive and negative weeks in the 52-week window.
Average skew4.4% / -2.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape74/100

Trend, activity pressure, participation, and risk combine to a 74/100 tape read.

 Indicator analysis83/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.

Activity pressure 0.97; 8 reversal markers Next-Week ExpectancyPositive 57.66%

Next-week expectancy is positive with a 57.66% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors57/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 38; Small Cap Core rank 98 SVQF25/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 544.0 of 725 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options46/100

LGND shows bearish options pressure with a 43/100 conviction score, put-call volume ratio of 2.50, expected move of 9.2%, and Sharemaestro trend signal active.

Bearish · Put-side pressure · Expected move 9.2% Sentiment55/100

Weighted news tone is neutral across 61 relevant articles.

Ligand Pharmaceuticals Inc (LGND) Institutional Confidence Insiders7 / 13

7 acquisitions and 13 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 2026287.5 USD-4.3%231.5 USD131.4 USD1.1426.601.6MOn
24 Jul 2026300.5 USD-0.9%228.2 USD130.0 USD1.4634.441.4MOn
17 Jul 2026303.4 USD-4.1%224.7 USD128.5 USD1.6835.131.7MOn
10 Jul 2026316.2 USD-1.0%221.3 USD127.0 USD1.7536.521.8MOn
3 Jul 2026319.6 USD5.3%217.1 USD125.4 USD1.7042.302.3MOn
26 Jun 2026303.6 USD10.4%212.6 USD123.8 USD1.4838.395.6MOn
19 Jun 2026274.9 USD7.6%209.2 USD122.3 USD1.2021.331.3MOn
12 Jun 2026255.5 USD7.8%206.7 USD121.0 USD0.9916.941.2MOn
5 Jun 2026237.0 USD2.2%204.9 USD119.9 USD0.6711.95931.1KOn
29 May 2026232.0 USD1.1%203.7 USD118.8 USD0.715.55692.1KOn
22 May 2026229.3 USD7.6%202.4 USD117.8 USD0.788.191.1MOn
15 May 2026213.2 USD-3.7%201.0 USD116.8 USD0.762.60864.9KOn
8 May 2026221.4 USD-2.7%199.9 USD115.9 USD0.976.901.4MOn
1 May 2026227.4 USD-1.7%198.5 USD115.0 USD0.7016.601.2MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.